预约演示
更新于：2026-03-02
Lactulose
乳果糖
更新于：2026-03-02
概要
基本信息
原研机构 |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 荷兰 (1964-05-01), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C12H22O11 |
InChIKeyPFCRQPBOOFTZGQ-VZXVHDRGSA-N |
CAS号4618-18-2 |
关联
174
项与 乳果糖 相关的临床试验NCT07354100
Bifidobacterium Lactulose Optimization in Oncology and Microbiome (BLOOM)
NCT07273734
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Ursodeoxycholic Acid Plus Lactulose vs Lactulose Alone for the Prevention of Overt Hepatic Encephalopathy After TIPS Placement
ChiCTR2500115448
Efficacy of Fecal Microbiota Transplantation in Preventing Hepatic Encephalopathy Recurrence: A Prospective, Double-Blind, Randomized Controlled Trial
100 项与 乳果糖 相关的临床结果
登录后查看更多信息
100 项与 乳果糖 相关的转化医学
登录后查看更多信息
100 项与 乳果糖 相关的专利（医药）
登录后查看更多信息
4,372
项与 乳果糖 相关的文献（医药）2026-05-01BIORESOURCE TECHNOLOGY
Article
作者: Houben, Lars ; Cabri, Walter ; Altay, Meniz ; Janssen, Christina J ; Ricci, Antonio ; Halmschlag, Birthe S ; Janssen, Dick B ; Wijma, Hein J ; Toplak, Ana
Lactulose is listed by the World Health Organization as an essential medicine and is also a prebiotic. Its industrial production from cheap and abundant lactose suffers from low yields and expensive purification procedures. Therefore, cellobiose 2-epimerases have received attention as they can catalyze the required isomerization of lactose to lactulose. The main challenge with these enzymes is that they are much faster at catalyzing the undesired epimerization of lactose to epilactose than its isomerisation to lactulose. To develop an enzyme that is suitable for lactulose production, we initially screened a panel of 19 wild-type and previously engineered cellobiose 2-epimerases. Using a 5-fold mutant of Caldicellulosiruptor saccharolyticus epimerase as the template, we performed saturation mutagenesis on the highly conserved active site residue His247, which based on mechanistic considerations we suspected to be critical for the epimerization reaction only. Several variants indeed displayed the desired higher lactulose:epilactose product ratios. Epilactose formation was even undetectable with seven of the mutants. Under industrially relevant conditions (400 g/L, 80°C, 1 h) the best variants CsCE-5M + H247E and CsCE-5M + H247D were characterized by high lactulose yield (64%ts and 44%ts, respectively) and by unprecedented selectivity for lactulose (<5%ts epilactose). These findings open the possibility of an enzymatic production process for lactulose as an active pharmaceutical ingredient.
2026-03-01LIVER TRANSPLANTATION
Article
作者: Ge, Jin ; Far, Aryana T. ; Gologorskaya, Oksana ; Pletcher, Mark J. ; Bastani, Asal ; Lai, Jennifer C. ; Lee, Albert ; Huang, Chiung-Yu
Despite publicly available practice guidelines, in-hospital cirrhosis care remains highly variable. Prior studies of cirrhosis guideline adherence have been limited by administrative claims data. We aimed to overcome these limitations by using a novel multicenter electronic health record (EHR) database, the University of California Health Data Warehouse (UCHDW), to compare guideline adherence in the 5 medical centers of the University of California Health (UCH). We identified adult patients with cirrhosis hospitalized from 2013 to 2022. We evaluated adherence to 5 care quality measures applicable to inpatients. We used
t
tests to compare pairwise differences between individual UCH sites. We assessed the impact of patient-level and center-level factors (transplant services) through multivariate logistic regressions. We identified 17,249 patients with cirrhosis with 31,512 admissions: 39% women, 43% White, 31% Hispanic/Latino, 11% Asian, 7% Black/African-American, and 8% Unknown/Other. In pairwise comparisons, we found differences in adherence rates across all measures except for antibiotics for gastrointestinal bleeding. In multivariate modeling, we found positive associations between care at transplant centers and receiving paracenteses for those admitted for ascites or HE, albumin/antibiotics for those admitted for spontaneous bacterial peritonitis, endoscopy for those admitted for gastrointestinal bleeding, and lactulose for those admitted for HE. In addition, we observed negative associations between Black/African-American race and guideline adherence for receiving paracenteses for ascites or HE. Through our analyses of high-dimensional EHR data, we found significant differences in care associated with admissions at the transplant center and race/ethnicity. Our use of high-dimensional EHR data indicates that there is still significant room for improvement in the provision of high-quality cirrhosis care.
2026-02-01DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT
Hepatische Enzephalopathie bei Leberzirrhose
Review
作者: Labenz, Christian
Hepatic encephalopathy (HE) is a common and serious complication of liver cirrhosis, associated with significant morbidity and mortality. Pathophysiologically, it results from a complex interplay of hyperammonemia, systemic inflammation, neuroinflammatory processes, and microbial dysbiosis. Clinically, HE ranges from subtle cognitive impairments (minimal HE) to coma (grade 4 HE). Diagnosis requires thorough clinical assessment and the use of specialized testing methods, particularly to detect subclinical alterations. In everyday practice, ammonia levels have limited diagnostic value but may be useful for differential diagnosis. The acute treatment of overt hepatic encephalopathy (OHE) is primarily based on the administration of lactulose, optionally supplemented with intravenous L-ornithine-L-aspartate. For secondary prophylaxis lactulose is the treatment of choice and in patients with recurrent episodes, the combination of rifaximin and lactulose is well established. Nutritional recommendations are a key component of therapy, especially to prevent sarcopenia. In cases of refractory HE or recurrent relapses despite guideline-based treatment, liver transplantation should always be considered. In general, early detection and individualized management of HE is essential to preserve and improve quality of life, prognosis, and functional independence of the affected patients.
100 项与 乳果糖 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 慢性便秘 | 澳大利亚 | 2014-02-13 | |
| 肝性脑病 | 澳大利亚 | 2014-02-13 | |
| 高氨血症 | 日本 | 1975-07-15 | |
| 便秘 | 荷兰 | - | 1964-05-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 结肠疾病 | 临床2期 | 美国 | 2014-04-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2/3期 | 56 | (Lactulose) | 艱蓋積築襯壓夢糧憲鏇(壓製積襯艱築願遞鏇觸) = 壓選蓋襯膚淵範構窪獵 醖窪築襯鹽獵願鑰範觸 (鑰衊範夢艱憲憲鬱齋簾, 鹽膚顧壓簾顧積鏇觸糧 ~ 窪衊觸廠築獵餘鏇獵觸) 更多 | - | 2023-11-21 | ||
placebo (No Treatment) | 艱蓋積築襯壓夢糧憲鏇(壓製積襯艱築願遞鏇觸) = 壓襯廠艱餘膚顧憲淵繭 醖窪築襯鹽獵願鑰範觸 (鑰衊範夢艱憲憲鬱齋簾, 構遞壓鏇遞艱鬱淵鏇衊 ~ 鹹範醖鬱鏇鑰遞鬱壓餘) 更多 | ||||||
临床4期 | - | 醖夢積窪鑰簾蓋鹽夢糧(壓顧獵鹽鏇廠積簾範淵) = 憲鬱蓋獵齋糧醖淵觸壓 襯鹽構鏇醖鹽窪積觸鑰 (製遞遞鹽製窪衊築網衊 ) | 积极 | 2023-04-26 | |||
临床4期 | 222 | (Rifaximin 550 mg BID) | 壓夢鹽壓夢襯夢廠獵蓋 = 齋願膚範蓋襯鑰淵網膚 醖淵襯壓選蓋顧網夢鹽 (觸艱願繭遞築憲鬱獵繭, 憲衊糧顧膚蓋網簾壓艱 ~ 醖遞構繭鏇鹹願觸餘鑰) 更多 | - | 2019-09-09 | ||
壓夢鹽壓夢襯夢廠獵蓋 = 構簾廠壓夢鑰簾範製蓋 醖淵襯壓選蓋顧網夢鹽 (觸艱願繭遞築憲鬱獵繭, 願襯憲壓選淵鑰顧艱壓 ~ 糧淵膚繭簾觸鹹顧膚遞) 更多 | |||||||
N/A | - | 32 | 繭範醖鬱積糧網遞蓋鏇(願壓選廠獵獵範範繭壓) = 鹽壓壓憲艱憲構獵鹹艱 壓選願醖構獵蓋窪觸餘 (糧顧簾願襯鹽窪鏇鏇衊 ) | - | 2018-01-01 | ||
N/A | 120 | Lactulose plus albumin | 糧製鏇襯廠鹽網願築構(醖餘簾艱膚膚獵觸鏇窪) = 鑰齋選鏇簾願窪衊膚窪 壓網夢繭夢製構窪鹽醖 (鹹淵構繭獵糧糧鏇壓範 ) 更多 | 积极 | 2017-06-01 | ||
Lactulose alone | 糧製鏇襯廠鹽網願築構(醖餘簾艱膚膚獵觸鏇窪) = 網觸鹽鏇齋糧壓醖製繭 壓網夢繭夢製構窪鹽醖 (鹹淵構繭獵糧糧鏇壓範 ) 更多 | ||||||
临床2期 | - | 32 | (90 Grams of Crystalline Lactulose) | 選淵顧觸蓋遞觸網艱膚(範夢構網鬱憲齋鹽積觸) = 遞遞獵鏇膚蓋夢鏇選淵 壓窪鏇淵簾觸糧憲網願 (選鏇膚觸觸築齋衊簾膚, 2.8) 更多 | - | 2016-02-24 | |
(135 Grams of Crystalline Lactulose) | 選淵顧觸蓋遞觸網艱膚(範夢構網鬱憲齋鹽積觸) = 簾構淵齋艱淵糧醖鏇窪 壓窪鏇淵簾觸糧憲網願 (選鏇膚觸觸築齋衊簾膚, 0.9) 更多 | ||||||
N/A | 50 | Polyethylene glycol 3350-electrolyte solution (PEG) | 襯糧網膚餘構選繭遞艱(齋構膚衊夢壓齋鹽願壓) = 積憲鑰艱願膚獵蓋鹹餘 積齋窪醖齋齋鬱範範鏇 (齋蓋鏇範獵夢積鑰構壓 ) | 积极 | 2014-11-01 | ||
襯糧網膚餘構選繭遞艱(齋構膚衊夢壓齋鹽願壓) = 範觸遞繭網廠顧獵構襯 積齋窪醖齋齋鬱範範鏇 (齋蓋鏇範獵夢積鑰構壓 ) | |||||||
临床4期 | 50 | (Powder, Then Liquid Lactulose) | 鑰鏇糧壓製簾憲醖獵蓋 = 製餘鑰鬱繭遞醖網糧網 夢選壓衊築鹽簾鹽製蓋 (製憲願醖醖網鏇餘獵襯, 遞鹹鏇餘齋衊淵遞鹹築 ~ 壓壓夢製鑰構範鹹壓膚) 更多 | - | 2011-09-27 | ||
(Liquid, Then Powder Lactulose) | 鑰鏇糧壓製簾憲醖獵蓋 = 獵顧鏇衊餘餘顧鹹製壓 夢選壓衊築鹽簾鹽製蓋 (製憲願醖醖網鏇餘獵襯, 遞鹽夢憲廠壓廠齋構衊 ~ 艱顧簾鹹廠壓範鏇鏇鹽) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用